Pure Global
NCT06270199

Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.

Clinical Trial to Stablish the Security of Using Allogeneic Fetal Stem Mesenchymal Cells From Umbilical Cord, Expanded in Pre-term Patients Suffering of Bronchopulmonary Dysplasia.
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 2·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Bronchopulmonary Dysplasia
Drug/Device/Intervention
Control
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Location
La Coruña,Madrid,Madrid,Málaga,Sevilla,Valencia, Spain
Timeline & enrollment
Phase
Phase 2
Start date
Jan 11, 2024
End date
Dec 01, 2026
Enrollment
75 participants
Primary outcome

Security of MSC therapy in very low birth weight preterm babies at risk of developing bronchopulmonary dysplasia,feasibility variable

Summary

Bronchopulmonary dysplasia (BPD) is a disease that affects preterm newborn patients,
 preventing their lungs from developing properly. Allogeneic fetal stem mesenchymal cells from
 umbilical cord could reduce the prevalence of BPD in this patients.

ICD-10 classifications
Bronchopulmonary dysplasia originating in the perinatal periodCongenital bronchomalaciaBronchopneumonia, unspecifiedOther congenital malformations of bronchusDiseases of bronchus, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06270199
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06270199 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal and is currently Recruiting. The study focuses on Bronchopulmonary Dysplasia. Target enrollment is 75 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.